The results revealed that the serum levels of GF-β1, CTGF, MMP-2, HA, PCIII, LN and PCI in CHF patients were decreased, and the clinical efficacy of the control group (50%) was better than that of the observation group (63%), indicating that CHF combined with conventional biomedicine medicine plus YQHYD can improve clinical symptoms and improve cardiac function; the mechanism may be related to the reduction in MF. The gene discussed is CCN2; the disease is congestive heart failure.